Quarterly ResultMay 19, 2026, 05:17 PM
Wellgistics Health Q1 Revenue $0.929M; Q2 Projected $1.775M; Strategic Updates
AI Summary
Wellgistics Health, Inc. reported its first quarter 2026 financial results, showing significant sequential revenue growth and a substantial reduction in net operating loss. The company's Q1 2026 revenue reached $0.929 million, with Q2 2026 projected to hit $1.775 million. Strategic initiatives include a joint venture with Kare Pharmtech to expand telepharmacy capabilities and a partnership with Tollo Health for medical foods and AI-driven health tools. Additionally, the company terminated non-binding letters of intent with Neuritek and WellCare to streamline its focus.
Key Highlights
- Wellgistics Health Q1 2026 revenue was $0.929 million, up from $0.486 million in Q4 2025.
- Q2 2026 projected revenue is $1.775 million, with $0.86 million already recognized through May 18, 2026.
- Wellgistics Pharmacy monthly revenue increased from $0.1 million in November 2025 to $0.6 million in April 2026.
- Net operating loss decreased significantly to $7.742 million in Q1 2026 from $32.430 million in Q1 2025.
- Net operating loss per share was $0.07 in Q1 2026, down from $0.62 in Q1 2025.
- Completed a joint venture with KareRx, adding telepharmacy capabilities and access to over 200,000 patient lives.
- Formed a strategic partnership with Tollo Health for medical foods, telemedicine, and AI coaching via the
- Health Lives Here
- app.
- Terminated previously announced non-binding letters of intent with Neuritek and WellCare.
Price Impact
More from WGRX